Biolinerx Financials

Biolinerx (BLRX) reported $1.2M in total revenue for fiscal year 2025. This represents a -95.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Biolinerx (BLRX) revenue declined by 95.9% year-over-year, from $28.9M to $1.2M in fiscal year 2025.

No, Biolinerx (BLRX) reported a net income of -$2.0M in fiscal year 2025, with a net profit margin of -171.7%.

As of fiscal year 2025, Biolinerx (BLRX) had $3.3M in cash and equivalents against $977K in long-term debt.

Biolinerx (BLRX) had a net profit margin of -171.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Biolinerx (BLRX) has a return on equity of -8.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Biolinerx (BLRX) generated -$8.1M in free cash flow during fiscal year 2025. This represents a 81.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Biolinerx (BLRX) generated -$8.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Biolinerx (BLRX) had $40.9M in total assets as of fiscal year 2025, including both current and long-term assets.

Biolinerx (BLRX) invested $25K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Biolinerx (BLRX) had a current ratio of 1.95 as of fiscal year 2025, which is generally considered healthy.

Biolinerx (BLRX) had a debt-to-equity ratio of 0.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Biolinerx (BLRX) had a return on assets of -5.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2025 data, Biolinerx (BLRX) had $3.3M in cash against an annual operating cash burn of $8.1M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Biolinerx (BLRX) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Biolinerx (BLRX) has an earnings quality ratio of 3.99x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Biolinerx (BLRX) scores 23 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.